713P Treatment-free survival, with and without toxicity, after immuno-oncology vs targeted therapy for advanced renal cell carcinoma (aRCC): 42-month results of CheckMate 214
暂无分享,去创建一个
M. Atkins | M. Regan | T. Powles | L. Werner | D. McDermott | O. Jegede | C. Mantia | S. Huo | B. Stwalley | V. D. Tejo